RT Journal Article
SR Electronic
T1 Alcohol consumption and telomere length: observational and Mendelian randomization approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263720
DO 10.1101/2021.09.17.21263720
A1 Topiwala, Anya
A1 Taschler, Bernd
A1 Ebmeier, Klaus P.
A1 Smith, Steve
A1 Zhou, Hang
A1 Levey, Daniel F
A1 Codd, Veryan
A1 Samani, Nilesh
A1 Gelernter, Joel
A1 Nichols, Thomas E.
A1 Burgess, Stephen
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.17.21263720.abstract
AB Alcohol’s impact on telomere length, a proposed marker of biological age, is unclear. We performed the largest observational study to date and compared findings with Mendelian randomization (MR) estimates. Two-sample MR used data from a recent genome-wide association study (GWAS) of telomere length. Genetic variants were selected on the basis of associations with alcohol consumption and alcohol use disorder (AUD). Non-linear MR employed UK Biobank individual data. MR analyses suggest a causal relationship between alcohol and telomere length: both genetically predicted alcohol traits were inversely associated with telomere length. 1 S.D. higher genetically-predicted log-transformed alcoholic drinks weekly had a -0.07 S.D. effect on telomere length (95% confidence interval [CI]:-0.14 to -0.01); genetically-predicted AUD - 0.06 S.D. effect (CI:-0.10 to -0.02). Results were consistent across methods and independent from smoking. Non-linear analyses indicated a potential threshold relationship between alcohol and telomere length. Our findings have implications for potential aging-related disease prevention strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAT is supported by a Wellcome Trust fellowship (216462/Z/19/Z). KPE is funded by the UK Medical Research Council (G1001354 & MR/K013351/1) and the European Commission (Horizon 2020 732592). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This work was also supported by the Li Ka Shing Centre for Health Information and Discovery, NIH grant (TN: R01EB026859), the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014), and a Wellcome Trust award (TN: 100309/Z/12/Z). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UKB approval was obtained from the North West Multi-Centre Research Ethics Committee and the Patient Information Advisory Group. The UKB Board and Access Sub-Committee and the Biobank Ethics and Governance Council reviewed our data access application.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on successful application to the UK Biobank.